• Formalin-fixed, paraffin-embedded human lymph node stained with anti-CD45RA antibody using peroxidase-conjugate and DAB chromogen. Note the membrane staining of B-cells in mantle (strong) and in follicle (weak)

Anti-CD45RA antibody (Full length) [ZR118] (STJ180560)

SKU:
STJ180560

Shipping:
Free Shipping
Current Stock:
Host: Rabbit
Applications: IHC-P
Reactivity: Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit monoclonal antibody anti-CD45RA (Full length) is suitable for use in Immunohistochemistry research applications.
Clonality: Monoclonal
Clone ID: ZR118
Conjugation: Unconjugated
Isotype: IgG
Formulation: Tris-HCI buffer containing stabilizing protein (BSA) and <0.1% ProClin
Purification: Affinity purified
Dilution Range: 1:100-200
Storage Instruction: Store at 2‐8°C for up to 24 months. Predilute: Ready to use, no reconstitution necessary. Concentrate: Use dilution range and appropriate lab‐standardized diluent. Stability after dilution: 7 days at 24°C, 3 months at 2‐8°C, 6months at ‐20°C.
Immunogen Region: Full length
Specificity: Positive Control: Lymph node or tonsil
Immunogen: Recombinant full-length human PTPRC protein
Background CD45 is a family of single-chain transmembrane glycoproteins, consisting of at least four isoforms that share a common large intracellular domain. Their extracellular domains are rod-shaped heavily glycosylated. The different isoforms are produced by alternative messenger RNA splicing of three exons of a single gene on chromosome 1q31-32. CD45 is exclusively expressed in haematolymphoid cells. Almost all haematolymphoid cells, including precursor cells and mature B-and T-lymphocytes, granulocytes, monocytes/histiocytes and interdigitating reticulum cells and follicular dendritic cells, express CD45. This protein is detected in most haematolymphoid neoplasms, i.e., leukemias and malignant lymphomas. Overall, about 90% of malignant lymphomas are CD45 positive. CD45 is an essential marker in the primary tumor screening panel to identify haematolymphoid differentiation. Loss of CD45 in precursor B-cell neoplasms is a negative prognostic parameter.

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance